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STUDIES OF HYPOXEMIC/ 
REOXYGENATION INJURY: 
WITHOUT AORTIC 
CLAMPING 
VII. Counteraction of 
oxidant damage by 
exogenous antioxidants: 
Coenzyme Qlo 
Coenzyme Qlo (COQlo)is a natural mitochondrial respiratory chain con- 
stituent with antioxidant properties. This study tests the hypothesis that 
CoQao administered before the onset of reoxygenation  cardiopulmonary 
bypass, can reduce oxygen-mediated myocardial injury and avoid myocar- 
dial dysfunction after cardiopulmonary b pass. The antioxidant properties 
of CoQlo were confirmed by an in vitro study in which normal myocardial 
homogenates were incubated with the oxidant, t-butyihydroperoxide. Fif-
teen immature piglets (<3 weeks old) were placed on 60 minutes of 
cardiopulmonary b pass. Five piglets underwent cardiopulmonary b pass 
without hypoxemia (oxygen tension about 400 mm Hg). Ten others became 
hypoxemic on cardiopulmonary b pass for 30 minutes by lowering oxygen 
tension to approximately 25 mm Hg, followed by reoxygenation at oxygen 
tension about 400 mm Hg for 30 minutes. In five piglets, CoQao (45 mg/kg) 
was added to the cardiopulmonary bypass circuit 15 minutes before 
reoxygenation, and five others were not treated (no treatment). Myocardial 
function after cardiopulmonary bypass was evaluated from end-systolic 
elastance (conductance catheter), oxidant damage (lipid peroxidation) was 
assessed by measuring conjugated iene levels in coronary sinus blood, and 
antioxidant reserve capacity was determined by measuring malondialde- 
hyde in myocardium after cardiopulmonary bypass incubated in the 
oxidant, t-butylhydroperoxide. Cardiopulmonary bypass without hypox- 
emia caused no oxidant damage and allowed complete functional recovery. 
Reoxygenated hearts (no treatment) showed a progressive increase in 
conjugated iene levels in coronary sinus blood after reoxygenation (2.3 -+ 
0.6 A233 nm/0.5 ml plasma at 30 minutes after reoxygenation) and reduced 
antioxidant reserve capacity (malondialdehyde: 1219 --- 157 nmol/g protein 
at 4.0 mmol/L t-butylhydroperoxide), resulting in severe postbypass dys- 
function (percent end-systolic elastance = 38 --- 6). Conversely, CoQ1 o 
treatment avoided the increase in conjugated iene levels (2.1 -+ 0.6 vs 
1.1 - 0.3, p < 0.05 vs no treatment), retained normal antioxidant reserve 
(896 - 76 nmol/g protein, p < 0.05 vs no treatment), and allowed nearly 
complete recovery of function (94% _+ 7%, p < 0.05 vs no treatment). We 
conclude that reoxygenation of the hypoxemic immature heart on cardio- 
pulmonary bypass causes oxygen-mediated myocardial injury, which can be 
limited by CoQlo treatment before reoxygenation. These findings imply that 
coenzyme Q10 can be used to surgical advantage in cyanotic patients, 
because therapeutic blood levels can be achieved by preoperative oral 
administration of this approved rug. (J THORAC CARDIOVASC SURG 1995; 
110:1221-7) 
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R epair of cyanotic heart defects by the use of Lcardiopulmonary bypass (CPB) is becoming 
more frequent in infants and newborns) Postoper- 
ative myocardial dysfunction is, however, the major 
cause of morbidity and mortality despite successful 
surgical correction and is more common in infants 
than in adult cardiac patients. 2 
Conventionally, CPB is initiated in previously 
hypoxemic patients at hyperoxemic oxygen tension 
(P02) levels (i.e., 300 to 400 mm Hg) and may result 
in an "unintended reoxygenation i jury" without 
considering the deleterious effects of hyperoxemia. 
Recent clinical findings document that chronic cya- 
nosis depletes endogenous antioxidants in myocar- 
dium, 3 whereas hyperoxemic CPB per se can gener- 
ate oxygen free radicals. 4 We have speculated that 
such abrupt reoxygenation causes an unintended 
oxygen-mediated myocardial injury that adds to 
subsequent intraoperative ischemic injury and 
causes myocardial dysfunction after bypass, '6 This 
hypothesis supported by clinical reports that show 
evidence of myocardial lipid peroxidation in preis- 
chemic biopsy samples from cyanotic hearts, 7 inad- 
equate cardioplegic protection in cyanotic patients,  
and myocardial dysfunction in infants placed on 
extracorporeal membrane oxygenation support de- 
spite absence of surgical ischemia. 9 We have shown 
recently that myocardial dysfunction associated with 
lipid peroxidation occurs after reoxygenation of 
hypoxemic immature piglet hearts on the initiation 
of CPB, which could be ameliorated by the antioxi- 
dants, N-(2-mercaptopropionyl)-glycine a d cata- 
lase. 1° Unfortunately, these antioxidants are not 
available clinically. 
Coenzyme Q10 (CoQ10) is a natural constituent of 
the mitochondrial respiratory chain that plays an 
important role in the regulation of mitochondrial 
oxidative phosphorylation. 11 In addition, the antiox- 
idant property of CoQ10 has been shown in vitro 12 
and in vivo. 13' 14 This study tests the hypothesis that 
CoQlo can reduce in vitro lipid peroxidation in 
myocardial homogenates exposed to the oxidant 
t-butylhydroperoxide and limit reoxygenation i jury 
of in vivo hypoxemic immature heart. 
Material and methods 
Preparation. Twenty immature, 2- to 3-week-old Du- 
roc-Yorkshire piglets (3 to 5 kg) were premedicated with 
0.5 mg/kg diazepam intramuscularly, anesthetized with 30 
mg/kg pentobarbital intraperitoneally followed by 5 mg/kg 
intravenously each hour, and the lungs ventilated on a 
volume-limited respirator (Servo 900D, Siemens-Elema, 
Solna, Sweden) via a tracheostomy. All animals received 
humane care in compliance with the "Principles of Lab- 
oratory Animal Care" formulated by the National Society 
for Medical Research and the "Guide for the Care and 
Use of Laboratory Animals" prepared by the National 
Academy of Sciences, published by the National Institutes 
of Health (NIH Publication No. 86-23, revised 1985). The 
surgical preparation for CPB, including vessel cannulation 
for blood sampling and monitoring, is similar to that 
described previously. 6 
Experimental protocols 
In vitro lipid peroxidation i myocardial homogenates. To 
evaluate the antioxidant properties of CoQlo and define 
the appropriate CoQlo dose, myocardial tissue from five 
piglets that were anesthetized and observed for 5 hours 
was analyzed. They were not subjected to CPB or hypox- 
emia/reoxygenation, andsamples were homogenized and 
incubated with 2 mmol t-butylhydroperoxide and CoQ~o 
(0, 0.1, 0.2, and 0.4 ram) for 30 minutes at 37 ° C. The 
formation of thiobarbituric acid-reactive substances, an 
index of lipid peroxidation, was measured spectrophoto- 
metrically at 532 nm and a reaction curve was generated. 
A malondialdehyde standard curve was run simulta- 
neously, and lipid peroxidation was expressed as nano- 
moles malondialdehyde p r gram protein. The effects of 
CoQ~o at each concentration was assessed by comparison 
with malondialdehyde production without COQlo in par- 
allel studies (control). 
Nonhypoxemic control 
In vivo hypoxemia-reoxygenation study. Five normox- 
emic animals were anesthetized, instrumented, and ob- 
served over 5 hours to provide baseline (control) func- 
tional and biochemical data without CPB. 
Five other piglets underwent 60 minutes of CPB with- 
out hypoxemia, followed by 30 minutes of observation 
after CPB to determine the effects of CPB per se (CPB 
group). 
Experimental. All studies were performed inpiglets on 
CPB. In 10 piglets, 30 minutes of hypoxemia was produced 
on CPB by adding N2 in the gas mixture in the CPB circuit 
to reduce alveolar oxygen tension (Pao2) to approximately 
25 mm Hg. CPB flow rate was raised to maintain mean 
aortic pressure at 50 mm Hg and to avoid systemic 
acidosis. This hypoxemic interval was followed by 30 
minutes of reoxygenation CPB at Po 2 approximately 
400 mm Hg. 
No treatment. Five piglets were reoxygenated without 
CoQlo. 
CoQ1 o treatment. Five piglets were treated with COQlo 
(45 mg/kg) added to the CPB circuit 15 minutes before 
reoxygenation. This dose was selected to achieve the 0.2 
mmol blood concentration shown in the in vitro studies 
and accounted for the piglet blood volume and the 
dilution produced by the extracorporeal circuit volume. 
Final functional assessments were performed and spec- 
imens for biochemical analyses were obtained after 30 
minutes of observation after CPB. 
Measurements 
Hemodynamics. Cardiac output was determined by du- 
plicate injections of 1 ml of 4°C saline solution into a 
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central venous catheter. Cardiac index (CI), systemic 
vascular resistance index (SVRI), and left ventricular 
stroke work index (LVSWI) were calculated with the 
following equations: 
CI (ml/min/kg) = CO/body weight (kg) 
SVRI (mm Hg • min • L -  i . kg) = (MAP - CVP) 
(mm Hg). CO- 1 (ml/min) • BW (kg) 
LVSWI (g • m/kg) = (MAP - LAP) 
x CO × 0.0136/(HR × body weight [kg]) 
where MAP is mean aortic pressure, LAP is mean left 
atrial pressure, CVP is central venous pressure, and CO is 
cardiac output in liters per minute. 
Left ventricular contractility. Left ventricular (LV) pres- 
sure and conductance atheter signals were amplified and 
digitalized to inscribe LV pressure-vdlume loops. After 
the procedure for correction of parallel conductance, a 
series of pressure-volume loops under variable loading 
conditions was generated by rapid transient occlusion of 
the inferior vena cava during a 7-second period of apnea, 
at a control condition, and 30 minutes after CPB was 
discontinued.~5 
The end-systolic pressure volume relationship was an- 
alyzed by an interactive videographics data analysis com- 
puter program (Spectrum, Bowman Gray School of Med- 
icine, Winston-Salem, N.C.) on an 386/33 MHz IBM 
computer (IBM, Armonk, N.Y.), and LV performance 
was described as the slope of linear regression (end- 
~6 systolic elastance lEes]), as described previously. Post- 
bypass LV contractility was assessed by percent recovery 
of prebypass control value (percent Ees). 
Myocardial function was also evaluated by infusion of 
blood from the CPB circuit at 10 ml/min/kg over a 
3-minute period before and after CPB to inscribe Starling 
function curves as described previouslyJ ~ 
Myocardial tissue injury from oxidants 
Myocardial conjugated diene production. During hypox- 
emia and reperfusion, blood samples were taken from 
coronary effluent (coronary sinus blood) to assess changes 
in conjugated iene levels. Blood samples were centri- 
fuged immediately for 5 minutes at 1000g, and plasma (0.5 
ml) was then stored in liquid nitrogen for later measure- 
ment by the method of Lesnefsky and coworkers. 17 
Antioxidant reserve capacity. The myocardial endoge- 
nous antioxidant state was assessed by determining in 
vitro lipid peroxidation i cardiac tissues i  after comple- 
tion of each in vivo experiment by the method of Godin 
and coworkers i to assess the vulnerability to subsequent 
oxidant stress. 
Statistics. Data were analyzed with the use of the 
StatView V2.0 program (Abacus Concepts Inc., Berkeley, 
Calif.) on a Macintosh IIci computer (Apple, Inc., Cuper- 
tino, Calif.). Analysis of variance was used for intergroup 
comparison and the paired Student test was used for 
comparison of variables within experimental groups. Dif- 
ferences were considered significant at the probability 
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Fig. 1. Effect of CoQ~o on t-butylhydroperoxide-induced 
lipid peroxidation of myocardial homogenates. Control: 
myocardial homogenates incubated without COQlo. His- 
togram shows percent malondialdehyde production of 
control when adding CoQlo to homogenates. *p < 0.05 vs 
control. Note: axis of histogram starts at 50% of control. 
level ofp < 0.05. Group data were expressed as mean plus 
or minus standard error of the mean. 
Results 
In vitro lipid peroxidation. Intact myocardial ho- 
mogenates were exposed to the oxidant, t-butylhy- 
droperoxide (2 retool/L) to induce lipid peroxida- 
tion with varying concentrations of CoQ10 (0, 0.1, 
0.2, and 0.4 mmol/L). For comparison, malondial- 
dehyde elution without CoQlo was considered 
100%. The addition of CoQ10 to the myocardial 
homogenates suppressed malondialdehyde produc- 
tion by 18% to 25% in a dose-dependent fashion 
(Fig. 1). 
In vivo hypoxemia-reoxygenation study 
Hemodynamics. Systemic (CPB) flow averaged 
100 ml/min/kg in control studies without hypoxemia 
(Table). Hypoxemia on CPB caused systemic vaso- 
dilatation in all studies, as SVRI fell to approxi- 
mately 65% below prehypoxemic values. Conse- 
quently, perfusion flow rate was increased initially to 
approximately 150 ml/min/kg during hypoxcmia to 
keep perfusion pressure approximately 50 mm Hg 
and reduced thereafter to maintain that pressure. 
Systemic pH remained between 7.3 and 7.4 in all 
studies, and no supplemental NaHC % was needed. 
CoQ10 supplementation f the CPB circuit did not 
change systemic vascular esistance. 
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Fig. 2. Postbypass myocardial contractility. LV Ees after 
discontinuation f CPB, expressed as percent of individual 
per hypoxemic values. CPB: piglet s undergoing CPB 
without hypoxemia, no treatment: piglets undergoing hy- 
poxemia/reoxygefiation without CoQ m and COQlo- 
treated piglets with CoQlo. *p < 0.05 vs CPB; tp < 0.05 
vs no treatment. 
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Fig. 3. Conjugated iene levels in coronary sinus plasma 
during hypoxemia and reoxygenation. CPB: piglets under- 
going CPB without hypoxemia, no treatment: untreated 
piglets undergoing hypoxemia/reoxygenation without 
CoQlo, and CoQlo: piglets treated with COQlo. *p < 0.05 
vs CPB and COQlo; 1"p < 0.05 vs pre-CPB values. 
LV performance. CPB per se did not  change 
LVSWI from control levels. In contrast, reoxygen- 
ation without CoQ10 reduced LVSWI to 55% _+ 9% 
at LAP 10 mm Hg, whereas LVSWI recovered 
98% _+ i4% at comparable LAP in piglets treated 
with COQlo (Table). CPB without hypoxemia (CPB 
group) allowed complete recovery of Ees (Ees = 
Table. Hemodynamic changes before and after CPB 
% 
Before CPB After CPB recovery 
Cardiac index 
(ml/min/kg) 
CPB (no hypoxia) 114 -+ 18 82 + 8 76 -+ 10 
No treatment 112 -+ 8 74 + 7 69 + 10 
CoQlo 115 +_ 8 104 + 13" 91 ___ 11 
Stroke work index 
(gm- m/kg) 
CPB (no hypoxia) 0.47 _+ 0.06 0.55 + 0.04 117 +__ 6 
No treatment 0.49 +- 0.06 0.26 + 0.03 55 ± 9 
CoQlo 0.61 -+ 0.03 0.61 + 0.1" 98 ± 14" 
CPB: piglets placed on CPB without hypoxia (n = 5), no treatment: 
hypoxia followed by reoxygenation without CoQlo (n = 5), and CoQw: 
CoQ m 45 mg/kg in CPB circuit 15 minutes before reoxygenation (n = 5). 
*p < 0.05 vs no treatment. 
98% of pre-CPB values). Conversely, reoxygenation 
was associated with only 38% _+ 12% recovery of 
Ees (p < 0.05 vs CPB). The addition of CoQ10 to the 
CPB prime restored LV contractility to 94% _+ 12% of 
pre-CPB levels (p < 0.05 vs no treatment) (Fig. 2). 
Conjugated dienes. Conjugated diene levels in 
coronary sinus blood were unchanged in piglets 
placed on CPB without hypoxemia (Fig. 3). Reoxy- 
genation on CPB (no therapy) raised conjugated 
diene concentration at 60 minutes on CPB by 64% 
of pre-CPB value (1.3 -+ 0.1 vs 2.3 _+ 0.5,p < 0.05), 
whereas CoQx0 avoided elevation of conjugated 
diene levels in coronary sinus blood (2.3 _+ 0.5 vs 
1.2 _+ 0.2,p < 0.05). 
Antioxidant reserve capacity 
Reoxygenation ( o treatment) reduced antioxi- 
dant reserve capacity, because more malondialde- 
hyde was produced in myocardial homogenates in- 
cubated with the oxidant t-butylhydroperoxide. 
Conversely, antioxidant reserve capacity remained 
normal when CoQ10 was added to the CPB circuit 
before reoxygenation (Fig. 4): 
Discussion 
This study in immature piglets documents that 
abrupt reoxygenation after a brief period of hypox- 
emia produces myocardial dysfunction associated 
with signs of lipid peroxidation and depletion of 
endogenous antioxidants that can be avoided by 
adding CoQx0 to the CPB circuit before reoxygen- 
ation. The optimal CoQ10 dose was determined by 
in vitro studies. These results were then transferred 
to the in vivo model of hypoxemia on CPB to avoid 
the hemodynamic deterioration and acidosis that 
characterize the ventilator hypoxemia model and to 
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provide the first evidence that CoQ~0 limits cardiac 
reoxygenation i jury in immature subjects. 
The in vivo model of hypoxemia on CPB provides 
a reproducible xperimental setting that avoids he- 
modynamic deterioration during hypoxemia nd en- 
sures optimal systemic and myocardial blood supply. 
Nevertheless, we acknowledge the limitations of the 
acute hypoxemic model, because chronic cyanosis 
results in myocardial metabolic adaptations tomain- 
tain normal metabolism ~9 that do not occur in the 
acute preparation. The acute model, however, has 
some relevance to the clinical situation, because 
similar biochemical and functional results occur 
when hypoxemic infants undergo reoxygenation on 
CPB.7, 9 
Ventricular dysfunction after CPB in cyanotic 
heart disease may develop or persist after successful 
anatomic correction of congenital cardiac de- 
fects. 20-22 In the past this has been attributed to 
several pre-operative and peri-operative factors, in- 
cluding myocardial damage secondary to cyanosis, 
abnormal cardiac loading, and intraoperative isch- 
emic injury (i.e., global ischemia). 2°' 21 Our findings 
suggest hat reoxygenation i jury is an additional 
causative factor, because signs of lipid peroxidation 
followed reoxygenation and depletion of endoge- 
nous antioxidants was observed after CPB despite 
the absence of surgically imposed ischemia. These 
findings suggest that reoxygenated myocardium ay 
become more susceptible to subsequent ischemic 
insults during cardiac repair. This speculation is 
supported by the experimental studies in the chron- 
ically cyanotic newborn lamb z3 and clinical observa- 
tions showing impaired myocardial protection in 
cyanotic versus noncyanotic patients, a 
Exogenous CoQlo has been used extensively in 
studies of regional 24; 25 and global ischemia 26' 27 and 
heart preservation in adult hearts. 14 Ohhara and 
colleagues 26reported that pretreatment with CoQ~o 
preserved myocardial stores of adenosine triphos- 
phate and total adenine nucleotides during ischemia 
in the isolated rat heart preparation, which implies 
that CoQlo could maintain mitochondrial oxidative 
phosphorylation and adenosine triphosphate-gen- 
erating capacity during ischemia. In this study, we 
used soy lecithin-solubilized CoQlo, which was de- 
veloped to facilitate rapid distribution into the myo- 
cardium, and the dosage of COQlo (45 mg/kg) was 
derived from previous experimental studies 14' 24, 25 
using intravenous administration of this drug. The 
COQlo dose added to the CPB circuit was deter- 
mined by considering the dilutional effects of the 
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Fig. 4. Antioxidant reserve capacity. Vulnerability of hy- 
poxemic and reoxygenated myocardium to subsequent 
oxidant stress determined by exposing tissue to 0 to 4 
mmol/L t-butylhydroperoxide for 30 minutes at 37 ° C. 
MDA, Malondialdehyde (see text for description). Con- 
trol: piglets without CPB, no treatment: piglets undergo- 
ing hypoxemia/reoxygenation without CoQlo, and CoQlo: 
piglets treated with CoQlo. *p < 0.05 vs control and 
COQlo; t-BHP, t-butylhydroperoxide. 
added volume for priming CPB circuit and con- 
formed to optimal dose achieved by in vitro analysis 
(Fig. 1). Takada and colleagues 2 reported that 
3.3% of a radioactive dose of soy lecithin-[14C] 
CoQ10 entered the respiratory chain of the myocar- 
dial mitochondria within 30 minutes after injection, 
but we did not make direct mitochondrial measure- 
ment to confirm this. Nakamura and coworkers 29 
reported that exogenous [14C] CoQ10 accumulates 
in the inner membrane and matrix of mitochondria 
at 72 hours after intravenous administration. In 
addition, Suzuki and colleagues 3° observed that 
exogenous CoQ~0 entered the mitochondrial p asma 
membrane and cytosolic fraction of cultured myo- 
cytes without affecting the content of endogenous 
CoQ10. Therefore it is conceivable that exogenous 
CoQ m in the present experimental setting may act 
directly on the plasma nd mitochondrial membrane 
to protect against myocardial injury without accu- 
mulation in the mitochondria. 
The antioxidant properties of CoQ10, like to- 
copherol, are documented by in vitro studies 
of subcellular systems, including phospholipid 
vesicles, 31 submitochondrial particles, mitochon- 
dria, 32 and microsomes. 33Furthermore, the anti- 
oxidant properties of CoQ10 have been demon- 
strated recently after ischemic stress. 13'14 The 
present studies of hypoxemic stress indicate that 
CoQ~0 avoids the depression of myocardial con- 
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tractility, rise of conjugated iene levels, and reduc- 
tion of antioxidant reserve that otherwise follows 
reoxygenation. Hydroxy conjugated ienes are free 
fatty acid oxidation products that are possible mark- 
ers of lipid peroxidation, 34 and studies in isolated 
heart models document he association of lipid 
peroxidation and myocardial dysfunction 35'36 after 
reoxygenation. Our findings suggest strongly the 
salutary effects of adding CoQ10 to the CPB circuit 
are related to its antioxidant effects. 
In our in vitro study, incubation with CoQ10 
resulted in dose-dependent suppression of lipid 
peroxidation i myocardial homogenates xposed 
to t-butylhydroperoxide. Lipid peroxidation i this 
in vitro preparation is due to hydroxyl radicals and 
hydrogen peroxide-generating system, because 
both N-(2-mercaptopropionyl)-glycine and cata- 
lase produce similar inhibition of malondialde- 
hyde production, whereas uperoxide dismutase is
ineffectiveS We suspect that CoQ10 reacted with 
lipid free radicals or lipid peroxide radicals and 
limited the propagation reaction of lipid peroxi- 
dation. The concentrations of CoQ10 showing 
antioxidant properties in the present in vitro study 
(100 to 400 txmol/L) are consistent with those of 
Beyer, 33 who used rat liver microsomes, and could 
be achieved in the plasma at 30 minutes after 
intravenous administration of 15 mg/kg of this 
agentY Unfortunately, neither parenteral CoQ10 
nor other antioxidants, such as N-(2-mercaptopro- 
pionyl)-glycine and catalase, can be used clini- 
cally, because they are not yet approved for 
intravenous administration. However, CoQj0 is 
approved for oral administration i  children and 
adult, and blood levels similar to those achieved 
by intravenous injection have been reported after 
10 days of oral administration. 25 
We conclude that abrupt reoxygenation after 
brief periods of hypoxemia on CPB produces myo- 
cardial dysfunction associated with signs of lipid 
peroxidation and depletion of endogenous antioxi- 
dants and that this oxygen-mediated r oxygenation 
injury can be limited by adding CoQ10 to the CPB 
circuit 15 minutes before reoxygenation. These find- 
ings imply that CoQlo can be used to surgical 
advantage in cyanotic patients if our data are con- 
firmed by others, because therapeutic blood levels 
can be achieved by preoperative oral administration 
of this approved rug. 
The coenzyme Qlo used in these experiments was 
graciously provided by the Eisai Co., Ltd., Tokyo, Japan. 
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